Actithera
Last verified 2026-05-02. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $86.4Mattributed |
|---|---|
| Latest round | series-a, $70.2M, 2025-07-01attributed |
| Founded | 2021 |
| Headquarters | Oslo |
| Industry | bio |
| Stage | series-a |
| Website | actithera.com |
Actithera develops cancer treatments that attach radioactive isotopes to designed molecules that deliver radiation precisely to tumors. It serves cancer patients through personalized radioligand therapy. Its proprietary chemistry matches radionuclide half-life to compound residence time for prolonged tumor retention with strong safety.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-07-01 | series-a | $70.2M | undisclosed |
Detected tech stack
Nginx, WordPress, Yoast SEO 27.6, Google Analytics, Google Tag Manager, jQuery Migrate 3.4.1, imagesLoaded 5.0.0, Elementor 4.0.9, DoubleClick Floodlight, cdnjs, CookieYes, Python
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series A, $70.2M | attributed | crunchbase named as publisher. No document URL on file. |
| Total raised $86.4M | attributed | crunchbase named as publisher. No document URL on file. |
| Company existence | self-reported | actithera.com, read 2026-05-02 |
| Description | self-reported | actithera.com, read 2026-05-02 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.